.png)
Felycin™ Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our proprietary veterinary mTOR inhibitor Felycin™ to target early Hypertrophic Cardiomyopathy (HCM) and was tested in stage B1 and B2 client-owned cats with the disease. Felycin™ prevented progression of hypertrophy.
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
Catch up on all the latest news from TriviumVet and their range of candidates targeting cardiology, pain, gastroenterology, age-related diseases and general wellness.
Congratulations to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award
At TriviumVet we are delighted to work with some of the veterinary industry's most passionate, knowledgeable and renowned thought leaders. We started working with Dr. Olby on the CHASE Questionnaire study to assess a novel pain management product in dogs. This award is an incredible recognition of her research career and achievements. Well done Dr. Olby!
TriviumVet Sponsor renowned ECVPT European College of Veterinary Pharmacology & Toxicology Event
TriviumVet proud to sponsor the European College of Veterinary Pharmacology and Toxicology (ECVPT) Cardiorenal Symposium in Bruges.
After selling two pharma firms, Louise Grubb is preparing for the US launch of a treatment for heart disease in cats
Grubb hopes to bring the new drug – Felycin – to market (in the US,
initially) early next year. Two other drugs – a beef-flavoured chewable
tablet for nerve pain in dogs and a treatment for canine gastric ulcers –
are also close to being market-ready. Alongside that, TriviumVet has
developed some diagnostic tests
%20CHASE.png)
Spotlight Series - The CHASE Questionnaire to Assess the Safety and Efficacy of a Novel Pain Management Product in Dogs
The goals of this study are to evaluate a newly developed questionnaire to assess pain and
clinical signs associated with CM/SM in dogs and to evaluate how well a novel veterinary
pain management product might treat the condition.
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
Dr. Joshua Stern and Victor Rivas of UC Davis to present cutting edge Feline Hypertrophic Cardiomyopathy (HCM) research to distinguished American College of Veterinary Internal Medicine (ACVIM).
TriviumVet CEO Louise Grubb wins IMAGE PwC Business Woman of the Year 2023 Award
Louise Grubb, founder and CEO of companion animal diagnosis and treatment business TriviumVet wins the IMAGE PwC Businesswoman of the Year Award 2023.
TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board
TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board. Helen takes the helm at an exciting time in the company's growth trajectory. Read more.......
